Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | GLP1R | P43220 | 2/20 | 0.34 |
| ▸ | SCTR | P47872 | 1/20 | 0.34 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.34 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 4/20 | 0.33 |
| ▸ | FNTB | P49356 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30607295 | 0.94 | OPRD1 (0.37) | OPRM1OPRD1OPRK1BACE1GLP1R | |
| SCHEMBL31514360 | 0.94 | PDCD1LG2 (0.37) | OPRM1OPRD1SLC6A2OPRK1BACE1 | |
| SCHEMBL31357356 | 0.94 | OPRM1 (0.36) | OPRM1OPRD1OPRK1PRMT1BACE1 | |
| SCHEMBL31391114 | 0.94 | SLC6A2 (0.36) | OPRM1OPRD1SLC6A2BACE1FNTA | |
| SCHEMBL30006221 | 0.93 | MAGI3 (0.40) | OPRM1OPRD1BACE1GLP1RKISS1R | |
| SCHEMBL29980611 | 0.92 | OPRM1 (0.36) | OPRM1OPRD1BACE1GLP1RSCTR | |
| SCHEMBL30254475 | 0.92 | OPRM1 (0.39) | OPRM1OPRD1SLC6A2BACE1MAGI3 | |
| SCHEMBL30974040 | 0.92 | OPRM1 (0.42) | OPRM1OPRD1OPRK1 | |
| SCHEMBL30645271 | 0.92 | PDCD1LG2 (0.38) | OPRM1OPRD1SLC6A2BACE1MAGI3 | |
| SCHEMBL31453800 | 0.90 | OPRM1 (0.40) | OPRM1OPRD1SLC6A2BACE1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | OPRM1 4101/4885OPRD1 4566/4885SLC6A2 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.